

Basic science (March–April 2005)

Articles in this list have been selected from material published since March 2005. They represent recommended reading only.

When available the citations are linked to the abstract held on PubMed (Medline) and CrossRef.

1. Aiello EJ, Buist DSM, Emily W, Porter PL. Association between mammographic breast density and breast cancer tumor characteristics [Abstract]. *Cancer Epidem Biomar* 2005; **14**: 662–668.
2. Atienza JM, Roth RB, Rosette C, Smylie KJ, Kammerer S, Rehbock J, Ekblom J, Denissenko MF. Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells [Abstract]. *Mol Cancer Ther* 2005; **4**: 361–368.
3. Barnes NLP, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast [Abstract]. *Clin Cancer Res* 2005; **11**: 2163–2168.
4. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte M, Jacquemier J, Viens P, Birnbaum D. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer [Abstract]. *Cancer Res* 2005; **65**: 2170–2178.
5. Bu X, Avraham HK, Li XY, Lim B, Jiang SX, Fu YG, Pestell RG, Avraham S. Mayven induces c-Jun expression and cyclin D1 activation in breast cancer cells [Abstract]. *Oncogene* 2005; **24**: 2398–2409.
6. Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwarl N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, Waxman J, Lemoine NR, Zelent A, Coombes RC, Ali S. Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF [Abstract]. *Gene Ther* 2005; **12**: 452–460.
7. Burwinkel B, Wirtenberger M, Klaes R, Schmutzler RK, Grzybowska E, Forsti A, Frank B, Bermejo JL, Bugert P, Wappenschmidt B, Butkiewicz D, Pamula J, Pekala W, Zientek H, Mielzynska D, Siwinska E, Bartram CR, Hemminki K. Association of NCOA3 polymorphisms with breast cancer risk [Abstract]. *Clin Cancer Res* 2005; **11**: 2169–2174.
8. Chatterton RT, Geiger AS, Mateo ET, Helenowski IB, Gann PH. Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: Effect of oral contraceptives and hormone replacement [Abstract]. *J Clin Endocr Metab* 2005; **90**: 1686–1691.
9. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R. Ethnicity and breast cancer: Factors influencing differences in incidence and outcome [Abstract]. *J Natl Cancer Inst* 2005; **97**: 439–448.
10. Constantinou AI, White BEP, Tonetti D, Yang YN, Liang WZ, Li WK, van Breemen RB. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours [Abstract]. *Eur J Cancer* 2005; **41**: 647–654.
11. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen L. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer [Abstract]. *J Clin Oncol* 2005; **23**: 1420–1430.
12. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells [Abstract]. *Oncogene* 2005; **24**: 2375–2385.
13. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR, Muller WJ,

- Moses HL. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis [Abstract]. *Cancer Res* 2005; **65**: 2296–2302.
14. Frank B, Hemminki K, Wirtenberger M, Bermejo JL, Bugert P, Klaes R, Schmutzler RK, Wappenschmidt B, Bartram CR, Burwinkel B. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk [Abstract]. *Carcinogenesis* 2005; **26**: 643–647.
 15. Fritah A, Saucier U, Mester J, Redeuilh G, Sabbah M. p21(WAF1/CIP1) selectively controls the transcriptional activity of estrogen receptor alpha [Abstract]. *Mol Cell Biol* 2005; **25**: 2419–2430.
 16. Garcia HH, Brar GA, Nguyen DHH, Bjeldanes LF, Firestone GL. Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and sub-cellular localization of the CDK2 protein complex [Abstract]. *J Biol Chem* 2005; **280**: 8756–8764.
 17. Gauthier ML, Pickering CR, Miller CJ, Fordyce CA, Chew KL, Berman HK, Tlsty TD. p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue [Abstract]. *Cancer Res* 2005; **65**: 1792–1799.
 18. Gronwald J, Jauch A, Cybulski C, Schoell B, Bohm-Steuer B, Lener M, Grabowska E, Gorski B, Jakubowska A, Domagala W, Chosia M, Scott RJ, Lubinski J. Comparison of genomic abnormalities between BRCA1 and sporadic breast cancers studied by comparative genomic hybridization [Abstract]. *Int J Cancer* 2005; **114**: 230–236.
 19. Gupta V, Carey JL, Kawakubo H, Muzikansky A, Green JE, Donahoe PK, MacLaughlin DT, Maheswaran S. Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model [Abstract]. *Proc Natl Acad Sci USA* 2005; **102**: 3219–3224.
 20. Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, Sellers TA. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa Women's Health Study [Abstract]. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 656–661.
 21. Heinonen N, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, Ristimaki A. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma [Abstract]. *Cancer Res* 2005; **65**: 2157–2161.
 22. Ise R, Han DH, Takahashi Y, Terasaka S, Inoue A, Tanji M, Kiyama R. Expression profiling of the estrogen responsive genes in response to phytoestrogens using a customized DNA microarray [Abstract]. *FEBS Lett* 2005; **579**: 1732–1740.
 23. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology [Abstract]. *Mol Endocrinol* 2005; **19**: 574–587.
 24. Jernstrom H, Sandberg T, Bageman E, Borg A, Olsson H. Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families [Abstract]. *Br J Cancer* 2005; **92**: 857–866.
 25. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR. Are breast density and bone mineral density independent risk factors for breast cancer? [Abstract]. *J Natl Cancer Inst* 2005; **97**: 368–374.
 26. Lee JE, Kim K, Sacchettini JC, Smith CV, Safe S. DRIP150 coactivation of estrogen receptor alpha in ZR-75 breast cancer cells is independent of LXXLL motifs [Abstract]. *J Biol Chem* 2005; **280**: 8819–8830.
 27. Ma YX, Tomita Y, Fan SJ, Wu KM, Tong YZ, Zhao ZG, Song LN, Goldberg ID, Rosen EM. Structural determinants of the BRCA1: estrogen receptor interaction [Abstract]. *Oncogene* 2005; **24**: 1831–1846.
 28. Maru D, Middleton LP, Wang SJ, Valero V, Sahin A. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger [Abstract]. *Cancer* 2005; **103**: 900–905.
 29. Menendez JA, Vellon L, Colomer R, Lupu R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erb B-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin (TM)) in breast cancer cells with Her-2/neu oncogene amplification [Abstract]. *Ann Oncol* 2005; **16**: 359–371.
 30. Mongan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RAR beta 2 in breast cancer cells [Abstract]. *Mol Cancer Ther* 2005; **4**: 477–486.
 31. Myers E, Hill ADK, Kelly G, McDermott EW, O'Higgins NJ, Buggy Y, Young LS. Associations and interactions between Ets-1 and Ets-2 and

- coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer [Abstract]. *Clin Cancer Res* 2005; **11**: 2111–2122.
32. Nagahata T, Sato T, Tomura A, Onda M, Nishikawa K, Emi M. Identification of RAI3 as a therapeutic target for breast cancer [Abstract]. *Endocr-Relat Cancer* 2005; **12**: 65–73.
 33. Najmi S, Korah R, Chandra R, Abdellatif M, Wieder R. Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells [Abstract]. *Clin Cancer Res* 2005; **11**: 2038–2046.
 34. Onodera Y, Hashimoto S, Hashimoto A, Morishige M, Mazaki Y, Yamada A, Ogawa E, Adachi M, Sakurai T, Manabe T, Wada H, Matsuura N, Sabe H. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities [Abstract]. *Embo J* 2005; **24**: 963–973.
 35. Perry MJ, Gujra S, Whitworth T, Tobias JH. Tamoxifen stimulates cancellous bone formation in long bones of female mice [Abstract]. *Endocrinology* 2005; **146**: 1060–1065.
 36. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling [Abstract]. *Science* 2005; **307**: 1625–1630.
 37. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques [Abstract]. *Br J Cancer* 2005; **92**: 906–912.
 38. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk [Abstract]. *Cancer Epidem Biomar* 2005; **14**: 699–704.
 39. Shinozaki M, Hoon DSB, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis [Abstract]. *Clin Cancer Res* 2005; **11**: 2156–2162.
 40. Sirchia SM, Ramoscelli L, Grati FR, Barbera F, Coradini D, Rossella F, Porta G, Lesma E, Ruggeri A, Radice P, Simoni G, Miozzo M. Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells [Abstract]. *Cancer Res* 2005; **65**: 2139–2146.
 41. Song H, Wang RX, Wang SM, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells [Abstract]. *Proc Natl Acad Sci USA* 2005; **102**: 4700–4705.
 42. Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei WZ, Musiani P, Lollini PL, Cavallo L, Forni G. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity [Abstract]. *Clin Cancer Res* 2005; **11**: 1941–1952.
 43. Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang DX, Jing T, Yu DH. ErbB2 promotes Src synthesis and stability: Novel mechanisms of Src activation that confer breast cancer metastasis [Abstract]. *Cancer Res* 2005; **65**: 1858–1867.
 44. Tang WG, Li Y, Yu DN, Thomas-Tikhonenko A, Spiegelman VS, Fuchs SY. Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells [Abstract]. *Cancer Res* 2005; **65**: 1904–1908.
 45. Tilli MT, Reiter R, Oh AS, Henke RT, McDonnell K, Gallicano GI, Furth PA, Riegel AT. Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice [Abstract]. *Mol Endocr* 2005; **19**: 644–656.
 46. Welm AL, Kim S, Welm BE, Bishop JM. MET and MYC cooperate in mammary tumorigenesis [Abstract]. *Proc Natl Acad Sci USA* 2005; **102**: 4324–4329.
 47. White KA, Yore MM, Deng DX, Spinella MJ. Limiting effects of RIP140 in estrogen signaling [Abstract]. *J Biol Chem* 2005; **280**: 7829–7835.
 48. Xu H, Yu YJ, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, Majumdar APN. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells [Abstract]. *Mol Cancer Ther* 2005; **4**: 435–442.
 49. Zeleniuch-Jacquotte A, Gu Y, Shore RE, Koenig KL, Arslan AA, Kato I, Rinaldi S, Kaaks R, Toniolo P. Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: Results of a prospective study [Abstract]. *Int J Cancer* 2005; **114**: 323–327.
 50. Zhao XS, Ayer RE, Davis SL, Ames SJ, Florence B, Torchinsky C, Liou JS, Shen L, Spanjaard RA. Apoptosis factor E124/PIG8 is a novel endoplasmic reticulum-localized bcl-2-binding protein which is associated with suppression of breast cancer invasiveness [Abstract]. *Cancer Res* 2005; **65**: 2125–2129.

Prepared by
R. Sutherland, J. Scorer
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia